Lance Laing
7PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Mar 04, 2026
Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy.Salmaan Khan, Jhomary Molden, Charles Iversrud
|Jun 26, 2025
Functional Analysis of the PI3K/AKT/mTOR Pathway Inhibitor, Gedatolisib, Plus Fulvestrant with and Without Palbociclib in Breast Cancer Models.Aaron Broege, Stefano Rossetti, Adrish Sen
|Oct 26, 2024
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib.Aaron Broege, Stefano Rossetti, Adrish Sen
|Aug 02, 2024
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway.Adrish Sen, Salmaan Khan, Stefano Rossetti
|Jun 05, 2024
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.Stefano Rossetti, Aaron Broege, Adrish Sen
|Jan 09, 2022
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.Ian A MacNeil, Salmaan A Khan, Adrish Sen
Pageof 2
